European Journal of Clinical Pharmacology · 2011 · 64 citations · 13 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyDrug Utilization ReviewDose CalculationDrug Utilization EvaluationMedication UsePharmacoepidemiologyAngiotensin Ii Receptor BlockersAntihypertensive Drug TherapyAntihypertensive Medication ClassesAntihypertensive TreatmentMedication Utilization PatternsPrescribed DosePrescription Drug Utilization PatternsThiazide Diuretic Therapy
PURPOSE: Defined daily doses (DDD) are used for the measurement of drug utilisation. The aim of the study was to analyse whether differences between DDD and prescribed daily doses (PDD) exist for relevant drug classes such as antihypertensive drugs and, if so, whether they primarily depend on drug classes or patient-related factors. METHODS: Using the data of a large German statutory health insurance scheme, we analysed continuous prescriptions for the following antihypertensive drug classes: thiazide diuretics, beta-blockers, dihydropyridine calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs). We summed the doses of all dispensed drugs per person during a defined time frame. We calculated the PDD (= total dose divided by the number of days) and expressed them as the PDD:DDD ratio (= amount of DDD per day and person). RESULTS: During the study period, 149,704 patients continuously received an antihypertensive medication. The average PDD:DDD ratio ranged from 0.84 (beta-blockers) to 1.88 (ARBs) and 2.17 (ACEIs). The average prescribed dosage of each drug class remained unchanged, even if the patients had previously received another antihypertensive drug with another PDD:DDD ratio. For example, if patients were switched from a beta-blocker to an ACEI, the PDD:DDD ratio increased, on average, from 0.79 to 2.17. Vice versa, the ratio decreased for patients with a drug change from an ACEI to a beta-blocker from 2.06 to 0.75. CONCLUSIONS: Even large differences between DDD and PDD seem to be a matter of drug classes and not primarily of patient characteristics.
13
Global burden of hypertension: analysis of worldwide data
Patricia M. Kearney, Megan Whelton, Kristi Reynolds et al. · The Lancet · 2005 · 7.7K citations
2007 Guidelines for the Management of Arterial Hypertension
Giuseppe Mancia, Guy De Backer, Anna F. Dominiczak et al. · Journal of Hypertension · 2007 · 5.8K citations
Institute for Quality and Efficiency in Health Care: Germany.
Mona Nasser, Peter T. Sawicki · PubMed · 2009 · 54 citations